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This report is based on the transcript of a roundtable debate
held at the 23rd International Symposium on Intensive Care
and Emergency Medicine, Brussels, Belgium, 18–21 March
2003. The participants of the debate were Steven Opal
(Pawtucket, RI, USA), Antonio Torres (Barcelona, Spain),
Marc Bonten (Utrecht, The Netherlands), Jonathan Cohen
(Brighton, UK), and Richard Wunderink (Memphis, TN, USA).
[Jean-Louis Vincent] ‘I’ stands for infection, and now we
would like together to try to characterize the extent of or the
severity of infection based on infection criteria. We will not
discuss the temperature or C-reactive protein or
procalcitonin because they will be the topic of the next
discussion, but let us rather focus on at least four aspects.
The first in my mind is the source of the infection. Of course,
in all our studies we record the source of infection but, for
instance, are urinary tract infections associated with a better
prognosis than pulmonary infections or infections coming
from other sites? The second question I have in mind is
about the degree of infection and how we can characterize it
— just as in the tumor/nodes/metastases classification the
size of the tumor is very important. We all know that
appendicitis is less severe than generalized purulent
peritonitis, so how can we quantify that? The third aspect
concerns hospital-acquired infection versus community-
acquired infection — how will this influence the prognosis?
And finally, what about the type of organism —
Pseudomonas versus other microorganisms against
Candida against others.
So let us start with the first question. What about the source
of infection — how will it influence our assessment and, in
particular, our assessment of the severity of the disease
state?
[Marc Bonten] Well, I confess I am a PIRO-naïve person but I
think one of the distinctions that must be made is whether
the infection is intensive care unit (ICU) acquired.
[JLV] We are talking about source first.
[MB] It depends how you define it. The most important
source is the respiratory tract; if you want to come to staging
of severity, it comes to staging of your diagnosis. If you base
your diagnosis of ICU-acquired pneumonia on just a tracheal
aspirate, the outcome will be much better for the group than
if you have a much more specific diagnostic tool, taking only
patients with much more severe pneumonia. So if you want
to say something about the severity of one certain type of
infection related to one source, it depends how you diagnose
it. I think that is my first impression.
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[Antonio Torres] The source may be related to the outcome
and to the severity as well, and it could be classified — I am
PIRO naïve as well — as abdominal, lung, urinary, central
nervous system. Then the second thing to be taken into
account with each of these sources is invasive or
noninvasive, localized or generalized? This is the second step
in the subclassification and is related to the prognosis. So in
the lung, for example, pneumococcal pneumonia with or
without bacteremia. Also, as you said, urinary tract infections
have not such a bad prognosis as lung infections. So this is
clear to me.
[JLV] That is actually a question that could be added to the
list: Does bacteremia by itself carry a worse prognosis?
[Richard Wunderink] I think that is a very important thing —
probably one of the best examples of this has already been
made by the surgeons, where the Surgical Infection Society
put together a way to classify intra-abdominal infections. They
did some clinical trials based on this, and it was based on a
different prognosis if you have diffuse peritonitis versus a
localized infection, and I think that kind of concept would be
good to start to apply to different types of infection. Obviously,
with urinary tract infections it makes a difference whether you
are talking about simple cystitis versus pyelonephritis — those
are clearly distinctions that we ought to make when we are
classifying patients – but I agree it comes back to definitions.
What does it require for you to say that it is pyelonephritis
rather than a urinary tract infection. So I think more work has
to be done on correct classification and correct diagnosis.
Can I jump ahead to the question about bacteremia? I’m not
sure that that is necessarily true — if you look at bacteremic
pneumococcal pneumonia, we have some outpatients with
bacteremia but that does not by itself mean it is a more severe
infection. And in fact, going back to the P concept, it might be
predisposed to not localizing infection but not having a severe
response. So I think that bacteremia is going to have to be
studied a lot more — I do not think we have definitively proved
that it carries a worse prognosis in all infection.
[Jonathan Cohen] I think we intuitively believe that the source
of infection has an impact on outcome, and what we have to
ask ourselves is what data are there to support that intuition?
At one level I think the data are there — in fact, more than in
other areas of PIRO actually — so if you look at specifically
the population of patients you are interested in, the septic
patient on the ICU, and you look at all the clinical studies that
have been done, and you correlate mortality with site of
infection, you can generally say that, let us say, lung
infections have a higher mortality than urinary or urosepsis-
related infections. Many studies address this — there is a very
old paper by Roberts in Clinical Infectious Diseases in which
he looked at all different sorts of infections and looked at the
rates of progression to severe outcome, and it was very clear
that you can draw Kaplan–Meier curves to show how quickly
the patient deteriorates, and so on. So I think at that level
there are data that would say, yes, the site of infection has an
effect on outcome.
But one has to be careful because it is not as simple as that.
Take bacteremia as an example: bacteremia caused by
Pseudomonas aeruginosa is clearly a different disease to
bacteremia caused by Staphylococcus epidermidis. So to
simply take location or source of infection in isolation, without
a wider context — a grid if you like, in which you are trying to
establish what is the overall risk associated with the
infection— is I think hazardous. So yes, source of infection is
part of the equation but cannot be taken in isolation.
In terms of whether bacteremia carries a worse prognosis, I
think we need to look at the data — and it is actually quite
interesting. If you look at bacteremia caused by different
organisms, you get different answers, and there is a great
danger here of trying to oversimplify something that is
actually rather complex. I am all in favor of oversimplification,
but only when it makes sense. So the answer to your
question is, exactly as Richard said, if you take the specific
context of community-acquired pneumonia with Streptococci
pneumoniae, there are data out there. If you look at the
specific context of candidemia, yes there are data out there.
But if you simply say, generally, does bacteremia have an
impact on outcome, you can probably get an answer — but it
probably is not a very meaningful answer because it is not
rich enough in information.
[Steven Opal] I totally concur with what Cohen just
mentioned. I would say about bacteremia that many of our
patients have catheter-related bacteremia, and that is an
entirely different set of problems from someone who has
secondary bacteremia from an uncontrolled, localized
infection. So if you look at those patients who have
bacteremic pneumonia or bacteremia associated with intra-
abdominal sepsis, you can show in a number of studies if you
look at large enough numbers that there is an adverse
outcome associated with bacteremia, probably as a
manifestation of two things. One is that you are getting
quantitative information about how heavy the infection is in the
localized area, and also how well the host is dealing with the
problem. If they are not dealing with the problem well they will
be bacteremic and likely to die, or if they have a massive
infection (undrained abscess, for example) and they are
bacteremic they are likely to do worse as well. However, if you
throw into that equation bacteremia from catheter-related
infection, particularly from coagulase-negative Staphylococci,
where the attributable risk of mortality associated with that is
in some studies zero, it can very substantially affect the
predictive value of bacteremia per se as an endpoint.
So I think what has been said is true but with the caveats that
you have to look at the origin of the bacteremia and what the
host has attached to the bacteremia as well.254
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[JLV] Let us jump perhaps on the tide of microorganisms
because time, of course, is very limited. So if I was showing
to you a big database, like the Sepsis Occurrence in the
Acutely ill Patients (SOAP) studies, what kind of analyses
would you like to do on the microbiologic data, again trying to
find a link between type of organisms and outcome — would
you take Candida, would you take resistant organisms,
methicillin-resistant Staphylococcus aureus versus
methicillin-sensitive Staphylococcus aureus.
[AT] This is very clear — for instance, take the lung as this is
my field — it is very clear that patients with community-
acquired P. aeruginosa pneumonia have a worse prognosis.
The second thing is that for Pseudomonas they will receive a
very different empirical treatment — that is very important to
know for Pseudomonas. Resistance is important as well –
methicillin-resistant Staphylococcus aureus pneumonia has a
worse prognosis than methicillin-sensitive Staphylococcus
aureus, for example. The other issue is the concentration of
bacteria in the site, because this is related to the
inflammatory response — it has been shown in animal models
and in humans as well, at least in the lung.
[MB] I think you should consider the combination of the
bacteria and the therapy that has been given. If you have a
bacteria considered to be a low-pathogenic bacteria that is
treated with the wrong antibiotics, the outcome may be
worse than for a high-pathogenic bacteria treated with the
right antibiotics. So I do not think that you can see them
separately from each other.
[RW] I am not sure that methicillin-sensitive Staphylococcus
aureus is different to methicillin-resistant Staphylococcus
aureus, because you are looking at very different patient
populations when you look at those two microorganisms — at
least in ventilator-associated pneumonia, not so much in
community-acquired pnemonia. So I think there clearly needs to
be some distinction between Gram-positive and Gram-negative
microorganisms; I would tend to want to split the Gram-
negative into Pseudomonas versus Enterobacteriaceae — I am
not sure there is a significant difference between an
Escherichia coli and a Klebsiella, and even Serratia.
[Derek C Angus] It seems to me that one of the things we
want to do with PIRO is use it, either in trials or in clinical
practice. So I can imagine that maybe we could know the
genetic predisposition ahead of time, but one of the things
that concerns me is that ‘I’ is going to be critical, and ‘I’
needs to be assigned within 2–3 hours of seeing the patient,
while administering therapy.
My question is simply about the timeliness of assigning the ‘I’
— it seems to me that you have a preliminary ‘I’, upon which
you have to make a treatment decision, and then later when
the cultures come back you might have another ‘I’. So this is
another issue: the notion of how PIRO will actually work.
[JC] There are some data that it makes some difference
whether it is Gram-positive or Gram-negative, and there are
several levels of that. First of all there are some interesting
and pretty obvious clinical data — the fact is that if you
thought you had someone with classic tampon-associated
staphylococcal shock syndrome, then you would use a
different kind of treatment and enroll them in a different kind
of trial than if you thought, on purely clinical grounds, that
they had a Gram-positive nosocomial pneumonia. I mean,
that is basic stuff. So in that sense it is obviously different. It
is also different in that we and others have published data to
show that there are different immunologic responses
according to whether it is Gram-positive or Gram-negative,
and interestingly it is now becoming increasingly clear that
there are different pathogenetic pathways. So even the basic
stuff — whether this is a round blue thing or a long pink thing
— may indeed have some impact on the kind of treatment you
do and on the way in which you enroll patients in a trial.
[Audience member] It is important to underline that if we do
not find the source of the infection the prognosis may actually
be worse, perhaps because we cannot cure the patient as
well as when we identify the source.
[Audience member] I think the practical use of this would
be that you could say, ‘I’ will be L for Lung, U for
microorganism unknown on day 1, and next day it is L
‘pseud’ or whatever the code is for Pseudomonas
plus/minus whether it is bacteremic plus/minus whether it is
appropriate or inappropriate antibiotic therapy. So I think if
the purpose of this is to try and speak a language that
everybody understands, to classify patients so that you can
group them together in clinically relevant ways, then I think
you are going to have to consider both source and
microorganism.
[Audience member] Would it be possible to quantify it in any
way?
[JC] Yes, one of the things that Tony mentioned in passing is
that one simple way in which you could do this, which is
analogous to the tumors/nodes/metastases thing, is to say
clearly it makes a difference as to whether you think this
organism is simply colonizing or whether it is causing a real
infection. So you could imagine you might say ‘I0’ is
colonization, ‘I1’ is local infection, ‘I2’ is deep infection, and
‘I3’ is systemic infection plus/minus toxin production. That
would be a practical approach that would be informative, but
would also be easily applicable.
[Audience member] But that comes very close to the
systemic inflammatory response syndrome and severe sepsis
classification.
[JC] No, because it refers specifically to what your
interpretation of that particular organism is in that patient.255
[Audience member] But if you have to make that judgment at
the bedside, you just look at clinical criteria.
[SO] I only want to point out that many of our patients have
polymicrobial infections, and that is where the PIRO system
might start to break down. We know now from a number of
experimental studies that some of these bacteria synergize
with each other in causing abscess formation, and one
organism might protect the other organism from antibiotic
exposure but also affect the immune response in a way that
allows the other to exist — so polymicrobial infection is
another topic that does not necessarily lend itself easily to a
nice easy source of classification.
[Audience member] I like this ‘I’ also because it is the only
way to remain connected to the real disease. It is not only the
microorganism, it is a microorganism in a site; and this is the
real disease — pneumococcal pneumonia with septic shock —
so it is far better to describe things like ‘severe pneumonia
with septic shock due to Pneumococcus’. This ‘I’ is the only
way for us to remain in the real world. The ‘I’ is both
microorganism and the organ.
[Audience member] I just wondered whether we are trying to
achieve two things with the same system? It has got to the
point now where you want a system to enroll people into
studies, and at the other end you want a system where you
have more data, like the genetics, like the patient history, like
the microbiological evidence. So maybe we need a late PIRO
score or a different system where we can construct better
analyses of our data.
[JLV] Do not forget that this is a quite flexible system and you
can adapt it to your own needs — whether it is to characterize
patients in your own ICU or for enrolling patients in a clinical
trial.
Now, the next question will be about community-acquired
infection versus ICU-acquired infection. In our clinical trials,
we enroll patients sometimes when they come in with severe
sepsis and sometimes when they develop sepsis after
10 days in the ICU — and my next question will be about how
different these are.
Data from the SOAP study showed that the prognosis is
about the same whether sepsis is present upon admission or
whether it develops after more than 48 hours. We were
surprised to find this, although immediately after that we saw
the results of the French EPISEPSIS study, where the same
kind of data came out in a study population that had more
than 3000 patients. So my question is, do hospital-acquired
infections — or at least infections acquired after at least
2 days in the ICU — have the same prognosis globally as
severe sepsis on admission? Of course it will depend on the
type of microorganism involved, but perhaps we could have
your reaction to these data, which are rather new.
[SO] I think that it is generally true that if you look at global
mortality statistics in nosocomially acquired infection versus
severe community-acquired infection, they are not a whole lot
different, but there are probably important differences in the
patient population. Patients in the community are reasonably
healthy and, in order to become septic, you have to have
bumped into a fairly virulent organism — whereas
nosocomially acquired patients are a surrogate for disease
severity, and these are typically abnormal patients, and the
bacteria that are now required to cause disease in these
patients can be substantially less virulent. So when you add
those together you wind up with similar mortality statistics —
so I am not surprised by those results.
[AT] I am not surprised about the results at 48 hours, but I
think that we should consider what happens later on —
7 days later it may be completely different. So the host is
different, a hospitalized patient in the ICU mechanically
ventilated with lots of antibiotics and some kind of
immunosuppression is a different type of host, although the
response is probably the same — just not the outcome.
[JLV] Can one expect that the attributable risk due to sepsis
is higher in community-acquired sepsis than in nosocomial
sepsis?
[RW] That is a very good question. I think if you look at it, it is
much much much easier to separate attributable mortality in
community-acquired infections — there you are talking about
this is the reason for admission, and yes they may have
underlying diseases but they are dying of infection. When
you talk about nosocomial pneumonia, and they have their
fifth episode of nosocomial pneumonia, they have had two
line infections with multiple different microorganisms, I think it
is incredibly difficult to have an attributable mortality. So it is
almost like comparing apples and oranges; I would say this
issue is more relevant to the ‘P’ discussion — this is past, or
predisposition — that is where you have to put this issue. Has
this patient been hospitalized, have they been ventilated for a
long period of time? Nosocomial pneumococcal pneumonia
has roughly the same mortality as community-acquired
pneumococcal pneumonia but it occurs in very different
populations.
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